The approval came as the US's fight against the pandemic has intensified again, with the highly infectious delta variant biting deeply into the progress that the country had made over the first half of the year
A health care worker displays a vial of the Pfizer-BioNTech COVID-19 vaccine during a vaccination event in Miami on Aug 5, 2021. The Food and Drug Administration on Monday, Aug. 23, 2021, granted full approval to Pfizer-BioNTech’s coronavirus vaccine for people 16 and older, making it the first to move beyond emergency use status in the United States. (Saul Martinez/The New York Times)
The Food and Drug Administration on Monday granted full approval to Pfizer-BioNTech’s coronavirus vaccine for people 16 and older, a decision that is likely to set off a cascade of vaccine requirements by hospitals, colleges and universities, corporations and other organizations.
Within hours, the Pentagon, CVS, the State University of New York system and the New York City school system, among others, announced that they would enforce mandates they had prepared but made contingent on the FDA’s action.
©2019 New York Times News Service